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SUMMARY
Objective: To investigate the safety/tolerability and efficacy of long-term adjunctive
zonisamide and its impact on growth and development in children (6–18 years) with
partial epilepsy.
Methods: Open-label extension of a phase III, placebo-controlled trial. Started with dou-
ble-blind transition period (2–11 weeks), during which patients on zonisamide continued
at the same dose and those on placebo switched to zonisamide 1 mg/kg/day, up-titrated
to 8 mg/kg/day (maximum 500 mg/day). During the subsequent open-label period (45–
57 weeks), zonisamide dosing could be adjusted according to tolerability/response. Safety
assessments included treatment-emergent adverse events (TEAEs), clinical laboratory
parameters, and vital signs. Efficacy assessments included responder rate (primary assess-
ment) and seizure freedom rate during the open-label period. Growth and development
assessments comprised Tanner stages, hand x-rays, Child Behavior Checklist (CBCL 6/
18), School Performance questionnaire, Physician and Parent/Guardian Global Impres-
sion of Change, andControlledOralWordAssociationTest (COWAT).
Results: One hundred forty-four children entered the study; 99 (68.8%) of 144 children
completed it, and 108 (75.0%) of 144 received zonisamide for ≥1 year. TEAEs occurred
in 39 (27.1%) of 144 patients. There were low incidences of serious TEAEs (2.1%) and
TEAEs leading to discontinuation (2.8%). Bicarbonate level decreases >3.5 mM
occurred in 64 patients (44.4%), and 24 patients (16.7%) had a weight decrease of ≥10%
from baseline. During the open-label period, 81 (56.3%) of 144 patients were respond-
ers and 16 (11.1%) of 144 achieved seizure freedom. Tanner staging and skeletal devel-
opment were as expected for the study population. Changes were minimal for CBCL
6/18 and School Performance scores. Most patients were “much improved”/“very
much improved” on Physician (73.8%) and Parent/Guardian (75.4%) Global Impres-
sions of Change. Median changes in COWATCategory and Letter Fluency scores were
2.0 and 0.5, respectively.
Significance: Adjunctive zonisamide was well tolerated and efficacious over a period of
at least 1 year in children with partial epilepsy, with no unexpected safety concerns
and no consistent detrimental effects on growth and development.
KEY WORDS: Development, Growth, Partial seizures, Pediatric epilepsy, Safety/tol-
erability, Zonisamide.
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The prevalence of epilepsy in children is approximately
0.5–0.7%.1 Although tolerability has improved with the
development of newer antiepileptic drugs (AEDs), more
than one fourth of pediatric patients remain refractory to
medical therapy.2 Consequently, there is still a need for
additional treatment options. Regulatory requirements for
pediatric epilepsy have become increasingly stringent3,4
and relatively few well-designed, randomized-controlled
trials have been performed in pediatric populations to
date.5–10 A particularly important aspect of the evaluation
of safety of a new agent in pediatric patients is the assess-
ment of the effects of long-term treatment on growth and
development.3
Zonisamide is a benzisoxazole derivative, chemically
unrelated to other AEDs, with a variety of modes of action,
including inhibition of Na+ channels and reduction of
T-type Ca2+ currents.11 It is currently licensed in Europe as
monotherapy for the treatment of partial seizures (with or
without secondary generalization) in adults with newly
diagnosed epilepsy, and for the adjunctive treatment of par-
tial seizures (with or without secondary generalization) in
adults, adolescents, and children aged ≥6 years.12 In the
United States, it is currently licensed as adjunctive therapy
in the treatment of partial seizures in adults with epilepsy.13
Results of a phase III, double-blind, randomized, pla-
cebo-controlled, multicenter trial have demonstrated that
adjunctive treatment with zonisamide is significantly more
effective than placebo in controlling seizures in pediatric
patients with partial seizures who are receiving a stable regi-
men of one or two other AEDs; the proportion of patients
experiencing a ≥50% reduction in seizure frequency from
baseline after 12 weeks of maintenance treatment being
50% for zonisamide versus 31% for placebo (p = 0.0044;
intention-to-treat [ITT] population, last observation carried
forward).10 Zonisamide was also shown to be well tolerated
compared with placebo, with no new or unexpected safety
findings observed in this setting.10
We present the results of an extension study conducted in
patients completing the initial phase III trial, designed to
investigate the safety/tolerability and efficacy of long-term
adjunctive zonisamide treatment in pediatric patients with
partial epilepsy, and to assess the impact of treatment on
growth and development.
Methods
This was an open-label extension study of a phase III,
double-blind, randomized, placebo-controlled, multicenter
trial (Study 312)10 that was conducted in order to assess the
long-term safety/tolerability and explore the long-term
maintenance of efficacy of adjunctive zonisamide treatment
in pediatric patients (age 6–18 years) with partial epilepsy
who were receiving one or two AEDs. Although the term
“focal epilepsy” is now preferred by some investigators,14,15
the term “partial” is used for this extension study, for the
sake of consistency with Study 312, which was conducted
in the same patient cohort and used the term “partial.”10 The
term “partial” is also still largely used within the neurologic
community and by regulatory agencies. Patients were
recruited from 28 sites in 10 European countries. The trial
was conducted in accordance with Good Clinical Practice
Guidelines and the protocol was approved by an indepen-
dent ethics committee. All patients (or their guardian or leg-
ally authorized representative) provided written informed
consent. The trial is registered with ClinicalTrials.gov,
number NCT01136954.
Patients
The study included male and female patients, aged
6–18 years, who were willing to give informed assent (writ-
ten or verbal), if applicable. If mandated by local regula-
tions, patients of relevant age were also required to provide
appropriate informed consent. In addition, patients had to
have completed Study 312; have a parent/caregiver willing
to provide informed consent (if the patient was under the
age of consent); and be in general good health, as deter-
mined by medical history, physical examination, and
screening laboratory results. Patients were excluded if they
had a history of renal calculi or renal insufficiency (creati-
nine level >135 lM [1.5 mg/dl]), or a history of demon-
strated noncompliance with treatment. Patients were also
excluded if they or their parent/guardian could reasonably
be expected not to be compliant with the study procedures
or to complete the study. Female subjects aged ≥10 years or
of childbearing potential (i.e., started menses) were
excluded if not either using or willing to use a medically
acceptable form of contraception (i.e., oral contraceptive
pill, surgical sterilization, implant or injected form of con-
traception, or intrauterine device), or prepared to abstain
from sexual activity for the duration of the study and for
1 month after last administration of study medication. If a
female subject became of childbearing potential during the
study, she had to be reconsented in order to undergo preg-
nancy testing, and either confirm abstinence or receive a
medically appropriate form of contraception.
Study design
The extension study started with a double-blind transition
period (duration 2–11 weeks) in order to preserve the blind-
ing of Study 312, during which patients already receiving
zonisamide continued on the same dose, while those who
previously received placebo commenced zonisamide treat-
ment, initiated at a dose of 1 mg/kg/day and then up-titrated
in weekly increments of 1 mg/kg to a target dose of 8 mg/
kg/day (maximum 500 mg/day; Fig. S1). During the subse-
quent open-label period (duration 45–57 weeks), zonisa-
mide dosing could be down-titrated, if required, in the event
of an adverse event (AE), down to the minimum dose for the
patient’s weight group; and up-titrated again, if required, to
control seizures, up to the maximum dose for the patient’s
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weight group. The overall dose range was 1–8 mg/kg/day.
The protocol assigned doses based on each patient’s weight
range (20 to <29, 29 to <42, 42 to <56, and ≥56 kg). The
weight ranges allowed a minority of patients whose weight
was toward the higher end of each range to be dosed at
<8 mg/kg/day and those whose weight was toward the
lower end of each range to be dosed at >8 mg/kg/day. The
maximum permitted dose was 500 mg/day. At the end of
the study, patients could apply to continue zonisamide under
the sponsor’s compassionate use policy; otherwise, zonisa-
mide dosing was down-titrated over a period of up to
4 weeks. The maximum total duration of the study was
59 weeks.
Assessments
Safety and tolerability
Safety assessments included the incidence of treatment-
emergent AEs (TEAEs), serious TEAEs, and withdrawal
due to TEAEs; clinical laboratory parameters (hematology,
biochemistry, immune system, thyroid hormones); vital
signs; and electrocardiography.
Efficacy
The primary efficacy assessment was the proportion of
responders during the open-label period, where response
was defined as a ≥50% decrease in 28-day seizure fre-
quency from Study 312 baseline. Secondary efficacy
assessments included the percentage change from Study
312 baseline in 28-day seizure frequency and the propor-
tion of patients experiencing the following changes from
Study 312 baseline in seizure frequency: 100% decrease
(seizure freedom), ≥75% decrease, ≥50% to <75%
decrease, ≥25% to <50% decrease, no change to <25%
decrease, >0% to <25% increase, ≥25% to <100% increase,
and ≥100% increase.
Growth and development
Assessments of the impact of treatment on growth and
development included Tanner stages (to assess sexual and
endocrine maturation), hand x-rays (to assess skeletal devel-
opment), Child Behavior Checklist for Children aged 6–18
(CBCL 6/18), School Performance questionnaire, Physician
Global Impression of Change, Parent/Guardian Global
Impression of Change, and Controlled Oral Word Associa-
tion Test (COWAT). Tanner stages are scales ranging from
1 to 5 that assess how developed a subject is in puberty
based on pubic hair (both males and females), genitals
(males only), and breasts (females only).16,17 Stage 2 or
above means that the subject has reached puberty. For
assessment of skeletal development, posteroanterior projec-
tion x-rays were taken of each patient’s left hand (including
the wrist and distal radius), and the radiographs were ana-
lyzed centrally (Perceptive Informatics Inc, Berlin,
Germany), with bone ages assigned by comparison with the
atlas standards of Greulich and Pyle.18 The CBCL 6/18
comprises a questionnaire assessing specific competencies
(20 items) and behavioral/emotional problems (118 items),
as reported by the patient’s parent/guardian. Scores are
based on ratings by the parent/guardian for how true each
item is “now or within the past 6 months” on a scale of 0–2,
where 0 = “not true (as far as you know),” 1 = “somewhat
or sometimes true,” and 2 = “very true or often true.” The
School Performance questionnaire is a teacher-rated scale
assessing effectiveness of learning, independent problem
solving, remembering of instructions, retention of informa-
tion, vocabulary, and hard working. Each patient is rated by
their teacher on a scale from 1 (“among the lowest in his/her
grade/year group/level”) to 5 (“among the highest in his/her
grade/year group/level”). The Physician and Parent/Guard-
ian Global Impressions of Change consist of a single ques-
tion (“Compared to the patient’s condition at baseline, how
much has the patient changed?”), where the patient’s physi-
cian and parent/guardian rate change as “very much
improved,” “much improved,” “minimally improved,” “no
change,” “minimally worse,” “much worse,” or “very much
worse.” COWAT measures a patient’s ability to make ver-
bal association with specified letters and detects changes in
word association fluency. It comprises two parts: Letter Flu-
ency, where the patient is given 1 min to list as many words
as possible beginning with a given letter (F, A, or S); and
Category Fluency, where the patient is given 1 min to list as
many words as possible belonging to a given category (e.g.,
“animals”). COWAT was assessed only in patients with an
intelligence quotient (IQ) of at least 75.
Statistics
The safety population was defined as all patients who
received at least one dose of study drug in the extension
study. No sample size calculation was performed. For effi-
cacy assessments, seizure frequency during a particular
study period was calculated as the average 28-day seizure
frequency during that period. Average 28-day seizure fre-
quency was calculated using the following formula: average
28-day seizure frequency = (number of seizures during yy
days) 9 28/yy. Responder rates (≥50% decrease [primary
assessment], 100% decrease, ≥75% decrease, ≥50% to
<75% decrease, ≥25% to <50% decrease, no change to
<25% decrease, >0% to <25% increase, ≥25% to <100%
increase, and ≥100% increase) were calculated and pre-
sented with 95% confidence intervals (CIs), calculated
using the Clopper-Pearson method. Percentage change in
28-day seizure frequency was summarized using descriptive
statistics and presented as median percentage change. Base-
line and demographic data were summarized using descrip-
tive statistics. The incidence and frequency of TEAEs were
summarized using the Medical Dictionary for Regulatory
Activities preferred terminology. Safety variables and
assessments of growth and development were described
using summary statistics; for these investigations, baseline
Epilepsia, 55(4):568–578, 2014
doi: 10.1111/epi.12548
570
R. Guerrini et al.
was defined as the assessment prior to starting zonisamide
treatment. Correlation between the Physician Global
Impression of Change and Parent/Guardian Global Impres-
sion of Change was assessed using Pearson’s correlation
coefficient.
Results
Patient population
Between July 10, 2008, and March 8, 2012, a total of 144
patients from 28 sites in Belgium (1), Estonia (1), France
(2), Hungary (5), Italy (1), Latvia (2), Poland (6), Spain (2),
Ukraine (7), and the United Kingdom (1) entered the exten-
sion study, having first completed Study 312. Of these, 72
patients had received placebo during Study 312 and 72 had
received zonisamide. All patients received at least one dose
of study drug during the extension study, and were therefore
included in the safety population. Overall, 99 (68.8%) of
144 patients completed the study; reasons for discontinua-
tion were lack of therapeutic efficacy (n = 27), withdrawal
of consent (n = 8), AE(s) (n = 5), physician decision
(n = 1), and “other” (loss to follow-up, n = 1; below weight
limit, n = 1; refusal to participate, n = 1; and consent form
not signed, n = 1). For patients who discontinued due to
lack of therapeutic efficacy or an AE, the median times to
withdrawal were 168 and 357 days, respectively. Demo-
graphic and baseline characteristics were similar between
patients who initially received zonisamide and placebo dur-
ing Study 312, except that the proportion of male patients
was slightly higher in the group that initially received pla-
cebo (55.6%) compared with the group that initially
received zonisamide (43.1%; Table S1).
Treatment exposure and dosing
The mean (standard deviation [SD]) time that patients
were in the extension study was 433.7 (169.9) days (median
444.5; range 15–721). Overall, 108 (75.0%) of 144 patients
were in the extension study for at least 1 year and exposed
to zonisamide for at least 1 year. During the open-label per-
iod, the mean (SD) zonisamide dose was 7.5 (1.1) mg/kg/
day (median 7.5; range 3.8–10.6). Overall, 128 (88.9%) of
144 patients received a dose of 5 to <9 mg/kg/day during
the open-label period; 2 (1.4%) of 144 received a dose of 0
to <5 mg/kg/day, and 8 (5.6%) of 144 received a dose of
9–12 mg/kg/day.
Safety and tolerability
During the transition, open-label, and down-titration peri-
ods, 41 (28.5%) of 144, 55 (39.9%) of 138, and 7 (5.9%) of
118 patients reported at least one TEAE, respectively. Dur-
ing the study as a whole, 70 (48.6%) of 144 patients reported
at least one TEAE; the most frequently reported TEAEs
were nasopharyngitis (10.4%), headache (6.9%), weight
decreased (6.9%), bronchitis (5.6%), and decreased appetite
(4.9%; Table 1). TEAEs that were judged to be possibly or
probably treatment related were reported by 39 (27.1%) of
144 patients; most commonly, weight decreased (6.3%),
decreased appetite (4.2%), and headache (2.1%) (Table 1).
The majority of TEAEs were of mild or moderate intensity,
and the incidence of TEAEs and treatment-related TEAEs
was generally similar between patients who had initially
received placebo and zonisamide in Study 312 (Table 1).
The incidence of TEAEs was also similar between patients
aged 6–11 years (34/67 [50.7%]) and 12–18 years (36/77
[46.8%]), and there were no TEAEs that were reported at a
notably different frequency by age group (data not shown).
Serious TEAEs were reported by 10 (6.9%) of 144 patients,
including three patients (2.1%) who experienced serious
TEAEs that were judged to be related to treatment. One
patient experienced severe renal colic (probably related)
and was withdrawn from the study, another patient experi-
enced severe abdominal pain (possibly related) and was
withdrawn from the study, and a third patient had a foot
fracture of moderate intensity (possibly related) but contin-
ued in the study with no change in zonisamide dose. There
were no deaths during the study. Four patients experienced
TEAEs that led to discontinuation (one patient experiencing
two TEAEs leading to discontinuation), but no specific
TEAE led to the discontinuation of more than one patient
(Table 1).
There were no clinically significant treatment-emergent
laboratory abnormalities. Decreases in bicarbonate levels of
>3.5 mM were observed in 64 patients (44.4%). Decreases
in bicarbonate were generally small to moderate; the mean
decrease from baseline (i.e., the assessment prior to starting
zonisamide treatment) to final visit was 1.8 mM. A bicar-
bonate value of ≤16 mM and a decrease from baseline of
≥6 mM were observed in four patients (2.8%), but no TE-
AEs of decreased bicarbonate were reported. A total of 24
patients (16.7%) had a decrease in weight of ≥10% from
baseline, and two patients (1.4%) had a decrease in weight
of ≥20% from baseline. There were no reports of serious
rash or hypersensitivity reactions, and no vital signs or elec-
trocardiographic parameters of clinical concern.
Efficacy
Primary assessment
During the open-label period, 81 (56.3%) of 144 patients
were responders (≥50% reduction in 28-day seizure fre-
quency from Study 312 baseline; 95% CI 47.7–64.5%;
safety population; Table 2; Fig. S2). Results were similar
for patients who initially received placebo in Study 312 (40/
72; 55.6%; 95% CI 43.4–67.3%) compared with those who
initially received zonisamide (41/72; 56.9%; 95% CI 44.7–
68.6%; Table 2; Fig. S2).
Secondary assessments
During the open-label period, 16 (11.1%) of 144 patients
achieved seizure freedom (100% reduction in 28-day
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Table 1. Summary of TEAEs (safety population)
Placeboa
N = 72
Zonisamideb
N = 72
Total
N = 144
Patients with TEAEs, n (%) 33 (45.8) 37 (51.4) 70 (48.6)
TEAEs reported by ≥3% patients in any group, n (%)
Nasopharyngitis 6 (8.3) 9 (12.5) 15 (10.4)
Headache 4 (5.6) 6 (8.3) 10 (6.9)
Weight decreased 6 (8.3) 4 (5.6) 10 (6.9)
Bronchitis 4 (5.6) 4 (5.6) 8 (5.6)
Decreased appetite 5 (6.9) 2 (2.8) 7 (4.9)
Respiratory tract infection 2 (2.8) 4 (5.6) 6 (4.2)
Rhinitis 3 (4.2) 3 (4.2) 6 (4.2)
Abdominal pain 2 (2.8) 3 (4.2) 5 (3.5)
Pharyngitis 3 (4.2) 1 (1.4) 4 (2.8)
Pharyngolaryngeal pain 3 (4.3) 1 (1.4) 4 (2.8)
Diarrhea 1 (1.4) 3 (4.2) 4 (2.8)
Patients with treatment-related TEAEs, n (%) 19 (26.4) 20 (27.8) 39 (27.1)
Treatment-related TEAEs reported by ≥2% patients in any group, n (%)
Weight decreased 6 (8.3) 3 (4.2) 9 (6.3)
Decreased appetite 4 (5.6) 2 (2.8) 6 (4.2)
Headache 0 3 (4.2) 3 (2.1)
Complex partial seizures 2 (2.8) 0 2 (1.4)
Aggression 2 (2.8) 0 2 (1.4)
Rash papular 2 (2.8) 0 2 (1.4)
Bradyphrenia 0 2 (2.8) 2 (1.4)
Patients with treatment-related TEAEs by intensity, n (%)
Mild 10 (13.9) 10 (13.9) 20 (13.9)
Moderate 8 (11.1) 8 (11.1) 16 (11.1)
Severe 1 (1.4) 2 (2.8) 3 (2.1)
Patients with serious TEAEs, n (%) 3 (4.2) 7 (9.7) 10 (6.9)
Patients with serious treatment-related TEAEs, n (%) 1 (1.4) 2 (2.8) 3 (2.1)
Patients with TEAEs leading to discontinuation, n (%) 2 (2.8) 2 (2.8) 4 (2.8)
TEAEs leading to discontinuation, n (%)
Nephrolithiasis 1 (1.4) 0 1 (0.7)
Renal colic 0 1 (1.4) 1 (0.7)
Ventricular extrasystoles 0 1 (1.4) 1 (0.7)
Abdominal pain 1 (1.4) 0 1 (0.7)
Status epilepticus 0 1 (1.4) 1 (0.7)
Patients with TEAEs leading to dose reduction, n (%) 4 (5.6) 3 (4.2) 7 (4.9)
TEAE, treatment-emergent adverse event.
aPatients who received placebo during Study 312.
bPatients who received zonisamide during Study 312.
Table 2. Grouped percentage changes from baseline in seizure frequency during the open-label period (safety
population)
Change from Study 312 baseline in seizure frequency
Placeboa
N = 72
Zonisamideb
N = 72
Total
N = 144
n (%) 95% CI n (%) 95% CI n (%) 95% CI
≥50% decrease (primary assessment) 40 (55.6) 43.4, 67.3 41 (56.9) 44.7, 68.6 81 (56.3) 47.7, 64.5
100% decrease (seizure freedom) 8 (11.1) 4.9, 20.7 8 (11.1) 4.9, 20.7 16 (11.1) 6.5, 17.4
≥75% decrease 27 (37.5) 26.4, 49.7 30 (41.7) 30.2, 53.9 57 (39.6) 31.5, 48.1
≥50% to <75% decrease 13 (18.1) 10.0, 28.9 11 (15.3) 7.9, 25.7 24 (16.7) 11.0, 23.8
≥25% to <50% decrease 10 (13.9) 6.9, 24.1 9 (12.5) 5.9, 22.4 19 (13.2) 8.1, 19.8
No change to <25% decrease 6 (8.3) 3.1, 17.3 9 (12.5) 5.9, 22.4 15 (10.4) 5.9, 16.6
>0% to <25% increase 6 (8.3) 3.1, 17.3 2 (2.8) 0.3, 9.7 8 (5.6) 2.4, 10.7
≥25% to <100% increase 5 (6.9) 2.3, 15.5 5 (6.9) 2.3, 15.5 10 (6.9) 3.4, 12.4
≥100% increase 1 (1.4) 0.0, 7.5 3 (4.2) 0.9, 11.7 4 (2.8) 0.8, 7.0
CI, confidence interval.
aPatients who received placebo during Study 312.
bPatients who received zonisamide during Study 312.
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seizure frequency from Study 312 baseline; 95% CI 6.5–
17.4%; safety population; Table 2; Fig. S2). Results were
identical for patients who initially received placebo and
zonisamide in Study 312 (for both populations: 8/72;
11.1%; 95% CI 4.9–20.7%; Table 2; Fig. S2). Results for
other grouped percentage changes from baseline in seizure
frequency demonstrated that 57 (39.6%) of 144 patients
experienced ≥75% reduction, 100 (69.4%) of 144
patients experienced ≥25% reduction, and 14 (9.7%) of 144
patients experienced ≥25% increase in seizure frequency
from Study 312 baseline during the open-label period; val-
ues were similar for patients initially receiving placebo and
zonisamide in Study 312 (Table 2).
The median percentage decrease in 28-day seizure fre-
quency from Study 312 baseline was 48.1% during the tran-
sition period and 65.9% during the open-label period (safety
population). Seizure frequency reduction was maintained
throughout the extension study, and results were similar for
patients who initially received placebo and zonisamide in
Study 312 (Fig. 1).
Growth and development
Tanner stages
Results for Tanner stages for pubic hair, genitals (males
only), and breasts (females only) were as expected for the
study population, and no differences were observed between
patients initially treated with placebo and zonisamide in
Study 312 (Table S2A). Similarly, results for transitions
between Tanner stages (Table S2B) and time between tran-
sitions of Tanner stages (data not shown) were as expected
for the study population, with no differences observed
between patients initially treated with placebo and zonisa-
mide. Mean (SD; median; range) age at entrance of stage 2
(puberty) for pubic hair growth was 10.6 (1.1; 11.0; 9–13)
years for patients initially treated with placebo in Study 312,
11.1 (1.2; 11.0; 10–13) years for patients initially treated
with zonisamide in Study 312, and 10.8 (1.2; 11.0; 9–13)
years for the overall population. The corresponding values
for age at entrance of stage 2 for genitals (males only) were
10.5 (0.8; 11.0; 9–11), 11.5 (2.4; 12.5; 8–13), and 10.9 (1.6;
11.0; 8–13) years, respectively; and for entrance of stage 2
for breasts (females only) were 9.5 (1.3; 9.5; 8–11), 11.3
(0.6; 11.0; 11–12), and 10.3 (1.4; 11.0; 8–12) years, respec-
tively.
Hand x-rays (skeletal development)
Results for skeletal development (bone age and delay in
maturation), before bone maturity and at bone maturity,
were as expected for the study population (Fig. 2). Delays
in bone maturation were minimal, and they were similar
between patients initially treated with placebo and zonisa-
mide in Study 312.
CBCL 6/18
Changes from baseline in CBCL 6/18 scores were mini-
mal throughout the course of the study (Table 3). For exam-
ple, median (mean) changes from baseline to open-label
visit 5 (weeks 62–71) were 1.0 (0.7) for Total Compe-
tence and2.0 (3.0) for Total Problems.
School Performance questionnaire
Changes from baseline in School Performance scores
were minimal throughout the course of the study (Table S3).
Physician and Parent/Guardian Global Impression of
Change
At all visits, the majority of patients for whom informa-
tion was recorded were reported as having improved on both
the Physician Global Impression of Change and the Parent/
Guardian Global Impression of Change, with good
correlation between the scales (Table 4). For example, at
Figure 1.
Median percentage decrease in
28-day seizure frequency from Study
312 baseline during the extension
study (safety population). OLV,
open-label visit.
Epilepsia ILAE
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open-label visit 5 (weeks 62–71), the percentage of patients
reported as “much improved”/“very much improved” was
73.8% on the Physician Global Impression of Change and
75.4% on the Parent/Guardian Global Impression of change,
and the Pearson’s correlation coefficient between the scales
was 0.8980.
COWAT
COWAT data were collected for 64 patients with an intel-
ligence quotient of at least 75. Although there was a high
degree of variability in the data, changes from baseline in
Category Fluency and Letter Fluency were generally mini-
mal, with no evidence of impairment with zonisamide treat-
ment (Table S4). For example, median (mean) changes
from baseline to open-label visit 5 (weeks 62–71) in Cate-
gory Fluency and Letter Fluency scores were 2.0 (2.4) and
0.5 (0.4), respectively.
Discussion
A key aspect of an AED’s clinical development is to
assess its safety and tolerability over the long term, since
important safety signals can take time to emerge or occur
too rarely to be picked up during the relatively short dura-
tion of the average phase III trial. The importance of this is
illustrated by the increased risk of visual field defects asso-
ciated with vigabatrin. This safety signal emerged only after
the drug was being widely used in clinical practice,19 and
was subsequently confirmed in a multinational, prospective,
observational study.20 When assessing an AED’s safety and
suitability for use in the pediatric population, it is crucial to
monitor additionally whether the agent has any effects on
growth and development over the long term.3 It is also
important to assess whether the efficacy of an AED is main-
tained long term, since patients can become tolerant to the
beneficial effects of treatment.21 The present study—an
open-label extension of one of only a few well-designed,
randomized, controlled trials to have been conducted in the
pediatric setting—provides information on the long-term
safety and efficacy of adjunctive zonisamide therapy in
pediatric patients with partial epilepsy. The study includes a
thorough evaluation of the potential effects of zonisamide
on growth and development, with three-fourths of those
included in the study having been exposed to zonisamide
treatment for at least 1 year.
The incidence of TEAEs in the extension study (49%)
was similar to that reported for patients treated with zon-
isamide and placebo in the initial trial (55% and 50%,
respectively).10 The majority of TEAEs reported in the
extension study were of mild or moderate intensity, and
there was a low incidence of serious TEAEs and TEAEs
leading to discontinuation. The most frequently reported
treatment-related TEAEs were weight loss and decreased
appetite, which is consistent with findings from the initial
trial.10 This is also consistent with adjunctive and mono-
therapy studies conducted in adult patients12,22: weight loss
of >5% occurring in approximately one third of adult
patients treated with zonisamide, particularly those who
are overweight prior to treatment.23 The mean decrease in
bicarbonate levels observed in the extension study
(1.8 mM) is also consistent with the known safety profile
for zonisamide.12 Overall, no new or unexpected safety
findings emerged following long-term zonisamide treat-
ment in this population.
This study also found that zonisamide displays no consis-
tent detrimental effect on long-term growth and develop-
ment, as assessed by Tanner stages, hand x-rays, CBCL 6/
18, School Performance questionnaire, Physician Global
Impression of Change, Parent/Guardian Global Impression
of Change, and COWAT. This is a particularly important
consideration when assessing a new treatment in the pediat-
ric setting.3 Although cognitive assessments were limited to
COWAT, it is encouraging that these results revealed no
evidence of impairment with zonisamide treatment; a
Figure 2.
Skeletal age and delay in maturation
(safety population).
Epilepsia ILAE
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finding that is supported by the lack of any effect on the
School Performance questionnaire.
During the open-label treatment period, the proportion of
responders (patients showing ≥50% seizure frequency
reduction from baseline in the initial trial) was 56%, consis-
tent with the responder rate observed in the initial trial
(50%),10 indicating that the efficacy of zonisamide is main-
tained with long-term treatment. This is further illustrated
by the fact that the median decrease in 28-day seizure fre-
quency observed in the maintenance period of the initial
trial (50%) was maintained throughout the extension study
(Fig. 1), the median decrease during the open-label period
being 66%. The proportion of patients achieving seizure
freedom during the open-label period was 11%, which was
also consistent with the 14% seizure freedom rate observed
in the initial trial.10
A potential limitation of this study was that growth and
development were assessed over a relatively short duration
of treatment (approximately 1 year), and consequently the
findings provide a useful snapshot of only the potential
effects of treatment on patients’ longer-term growth and
development. However, these parameters were additionally
monitored in the initial trial (median duration of treatment
exposure, 140 days)10 and it is encouraging that, overall,
Table 4. Physician and Parent/Guardian Global Impressions of Change (safety population)
Visit Score
Physician Global Impression of Change
Parent/Guardian Global Impression of
Change
Placeboa
N = 72
Zonisamideb
N = 72
Total
N = 144
Placeboa
N = 72
Zonisamideb
N = 72
Total
N = 144
Open-label visit 2 Not assessed 0 0 0 0 0 0
Very much improved, n (%) 8 (16.3) 13 (26.5) 21 (21.4) 8 (16.3) 16 (33.3) 24 (24.7)
Much improved, n (%) 15 (30.6) 16 (32.7) 31 (31.6) 18 (36.7) 13 (27.1) 31 (32.0)
Minimally improved, n (%) 12 (24.5) 7 (14.3) 19 (19.4) 7 (14.3) 6 (12.5) 13 (13.4)
No change, n (%) 9 (18.4) 11 (22.5) 20 (20.4) 7 (14.3) 8 (16.7) 15 (15.5)
Minimally worse, n (%) 5 (10.2) 1 (2.0) 6 (6.1) 7 (14.3) 2 (4.2) 9 (9.3)
Much worse, n (%) 0 1 (2.0) 1 (1.0) 1 (2.0) 2 (4.2) 3 (3.1)
Very much worse, n (%) 0 0 0 1 (2.0) 1 (2.1) 2 (2.1)
Missing 13 17 31 14 18 32
Pearson’s correlation coef. 0.9637
Open-label visit 3 Not assessed 0 0 0 0 0 0
Very much improved, n (%) 6 (17.1) 14 (36.8) 20 (27.4) 7 (20.0) 17 (44.7) 24 (32.9)
Much improved, n (%) 18 (51.4) 15 (39.5) 33 (45.2) 17 (48.6) 11 (29.0) 28 (38.4)
Minimally improved, n (%) 5 (14.3) 4 (10.5) 9 (12.3) 5 (14.3) 4 (10.5) 9 (12.3)
No change, n (%) 4 (11.4) 4 (10.5) 8 (11.0) 4 (11.4) 6 (15.8) 10 (13.7)
Minimally worse, n (%) 2 (5.7) 1 (2.6) 3 (4.1) 2 (5.7) 0 2 (2.7)
Much worse, n (%) 0 0 0 0 0 0
Very much worse, n (%) 0 0 0 0 0 0
Missing 15 18 33 15 18 33
Pearson’s correlation coef. 0.9867
Open-label visit 5 Not assessed 0 0 0 0 0 0
Very much improved, n (%) 6 (20.0) 11 (35.5) 17 (27.9) 9 (30.0) 10 (32.3) 19 (31.2)
Much improved, n (%) 16 (53.3) 12 (38.7) 28 (45.9) 13 (43.3) 14 (45.2) 27 (44.3)
Minimally improved, n (%) 4 (13.3) 4 (12.9) 8 (13.1) 4 (13.3) 3 (9.7) 7 (11.5)
No change, n (%) 2 (6.7) 2 (6.5) 4 (6.6) 0 2 (6.5) 2 (3.3)
Minimally worse, n (%) 2 (6.7) 2 (6.5) 4 (6.6) 3 (10.0) 2 (6.5) 5 (8.2)
Much worse, n (%) 0 0 0 1 (3.3) 0 1 (1.6)
Very much worse, n (%) 0 0 0 0 0 0
Missing 0 0 0 0 0 0
Pearson’s correlation coef. 0.8980
Open-label visit 7 Not assessed 0 0 0 0 0 0
Very much improved, n (%) 3 (23.1) 10 (71.4) 13 (48.2) 3 (23.1) 10 (71.4) 13 (48.2)
Much improved, n (%) 7 (53.9) 2 (14.3) 9 (33.3) 6 (46.2) 2 (14.3) 8 (29.6)
Minimally improved, n (%) 1 (7.7) 1 (7.1) 2 (7.4) 3 (23.1) 1 (7.1) 4 (14.8)
No change, n (%) 1 (7.7) 1 (7.1) 2 (7.4) 0 1 (7.1) 1 (3.7)
Minimally worse, n (%) 1 (7.7) 0 1 (3.7) 1 (7.7) 0 1 (3.7)
Much worse, n (%) 0 0 0 0 0 0
Very much worse, n (%) 0 0 0 0 0 0
Missing 0 0 0 0 0 0
Pearson’s correlation coef. 0.9347
aPatients who received placebo during Study 312.
bPatients who received zonisamide during Study 312.
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there has been no indication of any consistent detrimental
effects on growth and development with adjunctive zonisa-
mide treatment. These findings will need to be clarified fur-
ther with longer-term observation. As with any multicenter,
multinational investigation, another potential limitation of
this study was the probable heterogeneity of the study popu-
lation as a result of regional variation; however, this did not
appear to affect the robustness of the initial trial’s find-
ings.10 In addition, as an open-label extension of a previous
trial, this study is limited as it does not have a comparator
for zonisamide over the long term. It is also limited by the
different durations of zonisamide exposure experienced by
patients treated with zonisamide and placebo in the initial
trial. Nevertheless, it provides valuable information regard-
ing the long-term effects of adjunctive treatment with zon-
isamide in the pediatric population.
In summary, this extension study demonstrates that
adjunctive zonisamide therapy is well tolerated and effica-
cious when administered to pediatric patients with partial
epilepsy over a treatment period of at least 1 year. No new
or unexpected safety concerns emerged, and there was no
indication of any consistent detrimental effects on long-
term growth and development. Zonisamide could therefore
prove to be a valuable treatment option for pediatric patients
with partial epilepsy.
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Fig. S1. Study design.
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tics (safety population).
Table S2. (A) Tanner stages at baseline, study entry, and
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safety population).
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